SIRS Y90 Radioembolization of metastatic liver tumor available at St Francis Hospital Memphis since 2011.
Recent SIRFLOX study shows hope for those dealng with metastatic liver disease.
SIRFLOX key findings
SIR-Spheres Y-90 resin microspheres + mFOLFOX6 (+ bev*) in mCRC
- Statistically significant improvement of 7.9 months in median PFS in the liver,
from 12.6 to 20.5 months
- 31% reduction in risk of progression in the liver
- 3-fold increase in complete response rate in the liver
- Statistically significant increase in hepatic response rate